undamentalytics Newsletter
Sign in

Sutro Biopharma, Inc. income statement

In fiscal 2025, Sutro Biopharma, Inc. reported revenue of $102m, up 65.2% on the year before, operating income of −$158m (a -154.5% margin) and net income of −$191m, or −$22.49 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue605238434362681546210246
Research and development4455546677104137180252166145
General and administrative1516213337566063484133
Operating income1−19−37−55−71−99−129−89−238−158−146
Interest expense01212321———
Net interest income———−4———————
Income before tax————−32−106−117−89−225−191−181
Income tax—000003182−0−0
Net income2−20−35−119−32−106−119−107−227−191−181
Diluted EPS$0.00−$109.88−$15.32−$2.43−$0.99−$2.29−$2.35−$1.78−$29.40−$22.49—
Diluted shares (average)——2m2m3m5m5m6m8m8m—
EBITDA7−14−33−51−67−94−123−82−231−151−140

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SPRO vs STROEDIT vs STROLXRX vs STRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sutro Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sutro Biopharma, Inc.